The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors

Current Pharmaceutical Design

Volumn 11, Issue 14, 2005, Pages 1771-1777

  Wang, Z ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoprevention; Cyclooxygenase; Oral cancer; Selective COX 2 inhibitors

Indexed keywords

BETEL EXTRACT; BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA; ETODOLAC; INITIATION FACTOR 4E; INTERLEUKIN 10; INTERLEUKIN 12; MATRIX METALLOPROTEINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; TILMACOXIB; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CIGARETTE SMOKING; COLON CANCER; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; GENE OVEREXPRESSION; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; LEUKOPLAKIA; LUNG CANCER; LYMPH NODE METASTASIS; MEDICAL LITERATURE; MEDLINE; MOUSE; MOUTH CANCER; MOUTH LESION; MUTAGENESIS; NONHUMAN; ORAL SURGERY; PANCREAS CANCER; PLOIDY; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SKIN CANCER; STOMACH CANCER; TUMOR VASCULARIZATION; UPREGULATION; WESTERN BLOTTING;

ANTICARCINOGENIC AGENTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DNA, NEOPLASM; HUMANS; MEMBRANE PROTEINS; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS;

EID: 18744372748     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053764887     Document Type: Review

References (89)

1. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaranmaiah K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract (review). Ann N Y Acad Sci 2001; 952: 109-15.
2. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer (review). Head Neck 2002; 24: 792-9.
3. Mohan S, Epstein JB. Carcinogenesis and cyclooxygenase: The potential role of COX-2 inhibition in upper aerodigestive tract cancer (review). Oral Oncol 2003; 39: 537-546.
4. Sudb J, Reith A. Which putatively pre-malignant oral lesions become oral cancer (review)? J Oral Pathol Med 2003; 32: 63-70.
5. Hawkey CJ. COX-2 inhibitor. Lancet 1999; 353: 307-14.
6. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
7. Nikitakis NG, Hebert C, Lopes MA, Reynolds MA, Sauk JJ. PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells, Int J Cancer 2002; 98: 817-23.
8. Taketo MM. Cyclooxyganase-2 inhibitors in tumorigenesis. J Natl Cancer Inst 1998; 90:1529-36.
9. Jackel EC, Raja S, Tan J, Das SK, Dey SK, Griod DA, et al. Correlation of expression of cycloozygenase-2, vascular endothelial growth factor, peroxisome proliferators-activated receptor (delta) with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001; 127: 1253-59.
10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
11. Lindner DJ, Borden EC. Effects of tamoxifen and interferon-β or the combination on tumor-induced angiogenesis. Int J Cancer 1997; 71: 456-461.
12. Kawamori T, Rao CV, Seihbert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 998; 58: 409-12.
13. Masterrer JL, Leahy KM, Koki AT, Zweifel BS. Antiangiogenic and antitumoractivities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-11.
14. Taketo MM. Cyclooxygenase-2 inhibitor in tumorigenesis (Part 1). J Nat Cancer Inst 1998; 90: 1529-36.
15. Noble SC, King DS, Olutade JI. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Am Fam Physician 2000; 61: 3669-76.
16. Goldstein JL, Silverstein FE, Agrawal NM. Reduced risk of upper gastrointestinal ulcer complications with Celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-90.
17. Tsujii M, Kawano S, Tsuji S, Sawaoka H. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
18. Pendland A, Schoggins SJ, Scott GA, Khan KN, Han R. Reduction of NU-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20:1939-44.
19. Actula S, Grenman R, Laippala P, Syrjanen S. Cancer of the tongue in patients younger than 40 years. Arch Otolaryngol Head Neck Surg 1996; 122: 1313-19.
20. Moore SR, Hohnson NW, Peirce AM, Wilson DF. The epidemiology of tongue cancer: a review of global incidence. Oral Disease 2000; 6: 75-84.
21. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999; 83: 18-29.
22. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002; 52: 195-215.
23. Wattenberg LW. An overview of chemoprevention: current status and future prospects. Proc Soc Exp Biol Med 1997; 216: 133-41.
24. Lingen MW, Polverini PJ, Bouch NP. Retinoic acid and interferon a act synergistically as antiangiogenic and antitumor agents against human head and neck squamous. Cancer Res 1998; 58: 5551-58.
25. Hong WK, Bromer RH, Hong WK. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 1985; 56: 1242-45.
26. Hong WK, Lippman SM, Itri LM, Karp DD. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323:795-801
27. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro S. Nonsteriodal anti-inflammatory drugs and risk of digestive cancer sites other than the bowl. Cancer Epidemiol Biomark Prev 2000; 9:119-23.
28. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Nat Cancer Inst 1998; 90: 455-60.
29. Tucker ON, Dannerberg AJ, Yang EK, Zang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancrcatic cancer. Cancer Res 1999; 59: 987-990.
30. Wolf H, Saukkonenk AS, Karajalainen A, Vairo H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997-5001.
31. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-29.
32. Mohammed SI, Knapp DW, Bostwick DG, Foster RN, Khan KN, Masferrer J, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647-50.
33. Gupta S, Srivastave M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-8.
34. Hida T, Yatabe Y, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 3761-64.
35. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon caner cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 9: 2254-59.
36. Chan G, Boyle JO, Yang EK, Zhang YF, Sacks PG. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-4.
37. Tang DW, Lin SC, Chang KW, Chi CW, Chang CS, Liu TY. Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma- evidence for COX-2 induction by areca quid ingredients in oral keratinocytes. J Oral Pathol Med 2003; 32: 522-9.
38. Sakurai K, Urade M, Noguchi K, Kishimoto H, Ishibashi M, Yasoshima J, et al. Increased expression of cyclooxygenase-2 in human salivary gland tumors. Pathol Int 2001; 51: 762-9.
39. Nathan CA, Leskov IL, Lin M, Abreo FW, Shi R, Hartman GH, et al. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001; 92: 1888-95.
40. Mestre JR, Chan G, Zhang F, Yang EK, Sacks PG, Boyle JO, et al. Inhibition of cyclooxygenase-2 expression : an approach to preventing head and neck cancer. Ann N.Y Acad Sci 1999; 889: 6271.
41. Gallo O, Fabbroni V, Sardi I, Magnelli L, Boddi V, Franchi A. Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cells carcinomas. Biochem Biophy Res Comm 2002; 299: 517-24.
42. Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of head and neck: inhibition of proliferation by nonsteroidal anti-inflammatory drug. Anticancer Res 2002; 22: 2089-96.
43. Mestre JR, Subbaramaiah K, Sacks PG, Stimson P, Schantz SP, Tanabe T, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygensase-2 in human oral squamous carcinoma cell. Cancer Res 1997; 57: 2890-95.
44. Banerjee AG, Gopalakrishnan VK, Bhanttacharya I, Vishwanatha JK. Deregulated cyclooxygenase-2 expression in oral premalignant tissue. Mol Cancer Ther 2002; 1: 1265-71.
45. Itoh S, Matsuit K, Furuta I, TakanoY. Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor. Oral Oncol 2003; 39: 829-35.
46. Peng JP, Su CY, Chang HC, Chai CY, Hung WC. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the hypopharynx. Hum Pathol 2002; 33: 100-4.
47. Sudb J, Ari R, Sondresen JE, Kildal W, Boysen M, Koppang HS, et al. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 2003; 39: 497-505.
48. Renkonen J, Wolff H, Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 2002; 440: 594-7.
49. Grosch S, Tegeder I, Niederberger E. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742-44.
50. Brown WA, Skinner SA, Malcontenti-Wilson C. Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase I or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 2001; 48: 660-6.
51. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, et al. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2:544-51.
52. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologica activity and clinical implications. J Clin Oncol 2000; 18:1135-49.
53. Gallo O, Franchi A, MagneliL, Sardi I, Vannacci A, Boddi V, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3: 53-61.
54. Gatlo O, Masini E, Bianchi B, Bmschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous carcinoma. Hum Pathol 2002; 33: 708-14.
55. Sudb J, Kildal W, Risberg B, Koppang HS, Danielsen HE, Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001; 344: 127-78.
56. Mashberg A, Boffetta P, Winkelman R. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer 1993; 72: 1369-75.
57. Ayan N, Ayan I, Altli C, Guler SD. p53 overexpression in normal oral mucosa of heavy smokers. J Exp Clin Cancer Res 2000; 19: 529-9.
58. Chang YC, Tsai CH, Yang SH, Liu CM, Chou MY. Induction of cyclooxygenase-2 mRNA and protein expression in human gingival fibroblasts stimulated with nicotine. J Periodontal Res 2003; 38: 496-501.
59. Vishwanatha JK, Swinney R, Banerjee AG. Modulation of annexin I and cyclooxygenase-2 in smokeless tobacco-induced inflammation and oral cancer. Mol Cell Biochem 2003; 248: 67-75.
60. Sharan RN. Association of betel nut with carcinogenesis. Cancer J 1996; 9: 13-9.
61. Jeng JH, Ho YS, Chan CP, Wang YJ, Hahn LJ, Lei D, et al. Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. Carcinogenesis 2000; 21: 1365-70.
62. Kawamori T, Rao CV, Seibert K. Chemopreventive activity of elecoxib, a specific cyclooxygenase-2 in hibitor against colon carcinogenesis. Cancer Res 1998; 58: 409-12.
63. Harris RE, Alshafie GA, Abou-Issa H. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxyganase 2 inhibitor. Cancer Res 2000; 60: 2101-03.
64. Fischer SM, Lo HH, Gordon GB. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcin 1999; 28: 231-40.
65. Grabbs CJ, Lubet RA, Koki AT. Celecoxib inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60: 5599-602.
66. Armstron WB, Meyskens FL. Chemoprevention of head and neck cancer, Otolaryngol Head Neck Surg 2000; 122: 728-35.
67. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 78: 1073-77.
68. Sporn MB, Lippman SM. Chemoprevention of cancer. In: Hollan JF, Bast RC Jr, Morton DL, Frei E III, Kufe DW, Weichselbaum RR. Ed, Cancer Medicine. Baltimore, Williams & Wilkins Inc. 4th Edition 1997; 495-508.
69. Epstein JB, Gorsky M. Topical application of vitamin A to oral leukoplakia: A clinical case series. Cancer 1999; 86:921-7.
70. Papadimitrakopoulou V, Hong WK. Retinoids in head and neck chemoprevention. Proc Soc Exp Biol Med 1997; 216: 283-90.
71. Yamamoto K, Kitayama W, Denda A, Morisaki A, Kuniyasu H, Kirita T. Inhibitory effects of selective cyclooxygenase-2 inhibitors, nimesulide and etodolac, on the development of squamous cell dysplasias and carcinomas of the tongue in rats initiated with 4-nitroquinoline l-oxide. Cancer Lett 2003; 199: 121-9.
72. Yoshida K, Tanaka T, Kohno H, Sakata K, Kawamori T, Mori H, et al. A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression. Histol Histopathol 2003; 18: 39-48.
73. 2 synthesis. Clin Cancer Res 2003; 9: 1885-97.
74. Sheng H, Shao J, Kirkland SC. inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254:59.
75. Gulpta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21.
76. Sawaoka S, Kawano S, Tsuji S. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 274: G1061-G1067.
77. Zimmmermann KC, Sarbia M, Weber AA. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204
78. Hsu AL, Ching TT, Wang DS. The cyclooxygcnase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275:11397-403
79. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999; 90:1152-62.
80. Wang Z, Fluentes CF, Shapshay SM. Anti-angiogenic and chemopreventive activities in oral carcinoma cell. Laryngoscope 2003; 112: 839-43.
81. Wang Z, Fuentes CF, Shapshay SM. "Photo-chemoprevention" of oral cancer with laser and celecoxib. Laser Surg Med 2003; 32: 180-4.
82. Rich TA, Shepard R. COX-2 inhibitors radiation sensitizers for upper GI tract cancers: esophagus, stomach and pancreas. Am J Clin Oncol 2003; 26:S110-3.
83. Moore RJ, Zweifel BS, Heuvelman DM. Enhance antitumor activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU. Proc Am Assn Cancer Res 2000; 41:409-10.
84. Milas L, Kishi K, Hunter N. Enhancement of tumor response to Y-radiation by an inhibitor of cyclooxygenase 2 enzyme. J Natl Cancer Inst 1999; 91: 1501-4.
85. Kishi K, Petersen S, Petersen C. Preferential enhancement of tumor radioresponse by cyclooxygenase-2 inhibitor. Cancer Res 2000; 60: 1326-1331.
86. Wang Z, Polavaram R, Shapshay SM. Topical inhibition of oral carcinoma cell with polymer delivered Celecoxib. Cancer Let 2003; 198: 53-8.
87. Fitzpatrick FA. Cyclooxygenase enzymes: regulation and function. Curr Pharm Design 2004; 10(6): 577-88.
88. Pellecchia M, Reed JC. Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy. Curr Pharm Design 2004; 10(12): 1387-98.
89. Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Design 2004; 10(6): 647-57.